Want to see HK:2289 full AI Analyst Report?
2289 Stock Chart & Stats
HK$7.31
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$7.31
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.30 - HK$8.00
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.67K
Market Cap
HK$592.92M
Enterprise ValueHK$2.75B
Total Cash (Recent Filing)HK$530.00M
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)10.8
Beta-0.26
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.26%
Share Statistics
EPS (TTM)0.43
Shares Outstanding108,000,000
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)1.15
Price to Sales (P/S)0.16
P/FCF Ratio2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Revenue BaseRevenue remained relatively stable and increased 3.33% in 2025 after being roughly flat in 2024. This provides an established sales base and indicates modest ongoing demand, supporting continued operating activity and a foundation for further growth over the next several quarters.
Improving Gross MarginThe rise in gross margin from approximately 5.95% in 2020 to 7.66% in 2025 shows improved economics on revenue generated. If maintained, this structural progress can support stronger gross-profit generation and provide some protection against pressure on downstream earnings.
Strong 2025 Free Cash FlowFree cash flow reached approximately 263M in 2025 and was broadly aligned with net income, with a free-cash-flow-to-net-income ratio near 0.97. This supports the quality of reported earnings and gives the company internally generated cash to fund operations and financial commitments.
Bears Say
Rising Balance-Sheet LeverageDebt increased materially while equity remained fairly flat, pushing debt-to-equity from about 2.74 to 3.39. This indicates that balance-sheet expansion is increasingly debt funded, raising financial risk and reducing flexibility to absorb weaker earnings or fund future needs.
Thin And Declining Net ProfitabilityNet margin remains very thin at approximately 1.06% and has declined substantially from 2.17% in 2022, while net income also fell in 2025. Limited earnings conversion leaves less room to withstand operating pressure and makes returns more sensitive to small changes in costs or revenue.
Volatile Operating Cash FlowAlthough cash generation improved in 2025, operating cash flow has varied from negative in 2023 to positive in later years, and free-cash-flow growth was slightly negative in 2025. This volatility reduces confidence that strong cash conversion can be sustained consistently.
Charmacy Pharmaceutical Co., Ltd. Class H News
2289 FAQ
What was Charmacy Pharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Charmacy Pharmaceutical Co., Ltd. Class H lowest stock price was HK$4.30 and its highest was HK$8.00 in the past 12 months.
What is Charmacy Pharmaceutical Co., Ltd. Class H’s market cap?
Charmacy Pharmaceutical Co., Ltd. Class H’s market cap is HK$592.92M.
When is Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 145 days.
How were Charmacy Pharmaceutical Co., Ltd. Class H’s earnings last quarter?
Charmacy Pharmaceutical Co., Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$0.238 earnings per share for the quarter.
Is Charmacy Pharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Charmacy Pharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Charmacy Pharmaceutical Co., Ltd. Class H pay dividends?
Charmacy Pharmaceutical Co., Ltd. Class H pays a Annually dividend of HK$0.344 which represents an annual dividend yield of 6.26%. See more information on Charmacy Pharmaceutical Co., Ltd. Class H dividends here
What is Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate?
Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Charmacy Pharmaceutical Co., Ltd. Class H have?
Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding.
What happened to Charmacy Pharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Charmacy Pharmaceutical Co., Ltd. Class H reported an EPS of HK$0.238 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Charmacy Pharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2289
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charmacy Pharmaceutical Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.45%
12-Months-Change
Fundamentals
Return on Equity
7.70%
Trailing 12-Months
Asset Growth
18.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―